News

Shortly after the successful focus group to explore the industry perspective on preclinical research, the second working session on June 1st assessing the translational development phase looked at in silico models for personalised medicine. During this second meeting, the group, composed of five experts from the field, explored some common bottlenecks and potential solutions. The importance of high-quality data collection and sharing was debated, as well as the relevance of model validation for ensuring reliable results and regulation-related issues.

On May 26th 2021, the first working session organised in the context of PERMIT’s WP5, translational development of patient-stratification processes, was held as a virtual meeting. It analysed the pharmaceutical industry perspective on preclinical research for personalised medicine.

No generic approach for sample size estimation can be made in personalised medicine when designing a stratification cohort. The conclusion is drawn from the first stakeholder consultation by the PERMIT project which looked to identify approaches to estimate the number of patients needed to be included in a cohort for different types of stratification studies using machine learning.

The PERMIT Project held its second General Assembly meeting on the 15th of January 2021. All consortium members gathered to share the milestones and achievements of the first year, focusing on the outcomes of the scoping review of PM methodologies. During the meeting, the work plan for 2021 was also presented and discussed.

On December 1 and 2, 2020 the PERMIT project held its Gap Analysis Workshop. This important milestone of the project corresponds to the final phase of the scoping review process that was carried out in the first year of the project, under the lead of the Mario Negri Institute for Pharmacological Research. Representatives from all consortium members participated in the workshop, as well as representatives of the EMA, EUnetHTA and the CTFG, who are associated partners of the PERMIT project.

PERMIT has launched a brief survey to to map patient stratification strategies currently undertaken by industry. It will contribute to a better understanding of the challenges and opportunities in the translational development phase of personalised medicine clinical trials

An abstract about PERMIT's scoping review was selected by the Cochrane Colloquium. 

WP2 has now finalized the protocol for the PERMIT Scoping Review. It is now available on Zenodo. 

The official kick-off meeting of the PERMIT project took place on Friday, January 24th in Paris, France. All consortium participants and partners attended, and actively participated in discussions on all seven project work packages. 

ICPerMed has developed a vision of how the use of personalised medicine approaches will promote 'next-generation' medicine in 2030. 

The PERsonalised MedicIne Trials (‘PERMIT’) project on methodological standards for personalised medicine research has received a positive funding.